《大行》瑞银降荣昌生物(09995.HK)评级至“中性” 目标价升至63.8元

阿斯达克财经
16 Jun

瑞银研究报告指,荣昌生物(09995.HK) 年初至今股价已累升三倍,高于行业的64%升幅,主要因其管线产品的进展,而配股7.96亿元亦缓解集团紧张的财务状况。该行认为从12个月的角度来看,集团股价合理,近期主要的正面催化剂已于股价中反映,将评级由原先“买入”下调至“中性”。另外,将RC18的全球销售及估算开支纳入考虑,目标价由33.7元大幅上调至63.8元。(ss/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-06-13 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10